Valneva plunges then recovers: what’s really happening with the stock and the VLA2001 vaccine?
If you've been following this French biotech for the past decade, you know that rollercoaster rides are par for the course. But what happened to Valneva this week is enough to make even the most seasoned pros wince. The stock suddenly broke below €4.35, flirting with €3.89 before showing some signs of a rebound. A jolt like this always sets off alarm bells for retail investors. So, what’s behind this latest about-face?
Solid financial results, but a fickle market mood
Let's put things in perspective. Based on the financial results released a few days ago, the fundamentals are solid. Revenue is there, cash flow is on track, and the development of vaccine candidates is progressing. So why the drop? Because in the stock market, especially for a company of this size, the devil is in the expectations. The market was likely hoping for a more aggressive outlook, or bigger news on the progress of the highly anticipated Lyme disease vaccine.
But this is about science, not magic. Thomas Lingelbach, the CEO, stresses this every time he speaks: developing preventive vaccines for infectious diseases isn't something that happens overnight. VLA15 (the candidate for Lyme disease) is arguably the most closely watched program in the industry, because if it succeeds, it would be the first modern-day "golden goose" for this disease. But without the final green light, the stock price remains under pressure.
VLA2001, the COVID vaccine that changed the game... and expectations
We shouldn't forget where this started. With VLA2001, Valneva proved it could compete with the big players. This inactivated virus vaccine, used particularly within strict protocols, was a much-needed lifeline. For those following regulatory aspects, the Generic Protocol for ECDC Studies of COVID-19 Vaccine Effectiveness Against Confirmed SARS-CoV-2 Using Healthcare Worker Cohorts: Version 3.0 remains a key reference for evaluating real-world effectiveness.
But today, the market has a short memory. The COVID era is behind us, and investors don't want to hear about legacy vaccines. They want something new, something disruptive. Right now, Valneva finds itself in a bit of a lull, caught between the end of the COVID euphoria and the ongoing maturation of its Lyme pipeline. This is often the phase where stocks suffer the most, because traders don't like uncertainty. They prefer blockbuster quarterly announcements over quiet waiting periods.
Reasons for optimism (or caution) going forward
So, what should you do if you hold Valneva stock or are eyeing it with interest? Here are a few key points to consider:
- Cash and visibility: The company has secured funding and partnerships. It's not going anywhere anytime soon. The financial results confirm this: they have the resources to stay the course until the next major milestones.
- The Lyme timeline: VLA15 is the main catalyst. Upcoming data readouts, if positive, could literally send the stock soaring. It's a binary outcome, but with enormous potential.
- Thomas Lingelbach's experience: He's no novice. He's weathered far bigger storms than this minor market chill. His strategy, focused on developing preventive vaccines, remains consistent.
On the stock market, emotions are often amplified with stocks like these. The drop below €4.35 triggered stop-losses and automated selling, which mechanically amplified the move. That's standard. What's more interesting is to see if the stock can stabilize above this psychological threshold in the coming sessions. If so, the technical rebound could be just as sharp as the fall.
Let's be honest, betting on Valneva today means betting on the biotech of tomorrow, with all the risks and rewards that entails. But those who held on during the uncertain times with VLA2001 will remember: when the science delivers, the market always catches up eventually.